| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Tuberculosis | 34 | 1996 | 24 |
Why?
|
Antitubercular Agents | 21 | 1997 | 5 |
Why?
|
Mycobacterium tuberculosis | 25 | 1996 | 17 |
Why?
|
Tuberculosis, Multidrug-Resistant | 12 | 1997 | 2 |
Why?
|
Tuberculosis, Pulmonary | 12 | 1997 | 20 |
Why?
|
New York City | 34 | 1997 | 32 |
Why?
|
Tuberculin Test | 8 | 2002 | 12 |
Why?
|
AIDS-Related Opportunistic Infections | 10 | 1997 | 41 |
Why?
|
Rifampin | 7 | 1997 | 12 |
Why?
|
Contact Tracing | 6 | 2002 | 4 |
Why?
|
Drug Resistance, Multiple, Bacterial | 3 | 2002 | 12 |
Why?
|
Disease Outbreaks | 4 | 2003 | 61 |
Why?
|
Drug Resistance, Bacterial | 6 | 2001 | 21 |
Why?
|
Disease Notification | 3 | 2002 | 4 |
Why?
|
Emigration and Immigration | 5 | 2003 | 19 |
Why?
|
HIV Infections | 7 | 1998 | 136 |
Why?
|
Antibiotics, Antitubercular | 4 | 1997 | 3 |
Why?
|
Humans | 55 | 1993 | 1856 |
Why?
|
Adult | 32 | 1997 | 1317 |
Why?
|
Isoniazid | 6 | 2002 | 3 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2010 | 10 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2010 | 33 |
Why?
|
World Health Organization | 3 | 2005 | 19 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2009 | 7 |
Why?
|
Male | 36 | 1993 | 1553 |
Why?
|
Female | 37 | 1993 | 1643 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2009 | 10 |
Why?
|
Risk Factors | 14 | 1997 | 555 |
Why?
|
Middle Aged | 26 | 1993 | 1161 |
Why?
|
Adolescent | 17 | 1997 | 891 |
Why?
|
Aged | 21 | 1993 | 988 |
Why?
|
Outcome and Process Assessment (Health Care) | 2 | 2006 | 63 |
Why?
|
Directly Observed Therapy | 2 | 2005 | 4 |
Why?
|
Cross Infection | 5 | 1993 | 46 |
Why?
|
Patient Compliance | 2 | 2002 | 113 |
Why?
|
Child | 13 | 2002 | 749 |
Why?
|
Self Administration | 1 | 2005 | 14 |
Why?
|
Child, Preschool | 10 | 2002 | 554 |
Why?
|
Treatment Refusal | 1 | 2005 | 31 |
Why?
|
Public Health Administration | 4 | 2002 | 14 |
Why?
|
Quality Assurance, Health Care | 1 | 2006 | 83 |
Why?
|
Sputum | 8 | 2002 | 26 |
Why?
|
Drug Monitoring | 1 | 2004 | 33 |
Why?
|
Program Evaluation | 4 | 2002 | 115 |
Why?
|
Health Plan Implementation | 1 | 2003 | 20 |
Why?
|
Retrospective Studies | 11 | 2001 | 653 |
Why?
|
Multivariate Analysis | 5 | 1997 | 225 |
Why?
|
Homeless Persons | 3 | 2003 | 7 |
Why?
|
Laboratories | 1 | 2000 | 21 |
Why?
|
DNA Fingerprinting | 2 | 1997 | 7 |
Why?
|
Young Adult | 7 | 2008 | 380 |
Why?
|
Aged, 80 and over | 7 | 1997 | 599 |
Why?
|
DNA, Bacterial | 4 | 1997 | 67 |
Why?
|
HIV Protease Inhibitors | 1 | 1999 | 25 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2000 | 135 |
Why?
|
Treatment Outcome | 7 | 2001 | 661 |
Why?
|
False Positive Reactions | 4 | 1997 | 71 |
Why?
|
HIV Seropositivity | 2 | 2003 | 24 |
Why?
|
Urban Population | 2 | 2007 | 80 |
Why?
|
Case Management | 2 | 2006 | 19 |
Why?
|
Molecular Epidemiology | 3 | 2002 | 7 |
Why?
|
Cluster Analysis | 5 | 2002 | 66 |
Why?
|
Incidence | 6 | 2001 | 336 |
Why?
|
Genotype | 6 | 2001 | 175 |
Why?
|
Health Personnel | 2 | 2003 | 54 |
Why?
|
Polymorphism, Restriction Fragment Length | 4 | 1997 | 32 |
Why?
|
Occupational Exposure | 3 | 2003 | 53 |
Why?
|
Case-Control Studies | 2 | 2005 | 283 |
Why?
|
Cohort Studies | 4 | 2001 | 332 |
Why?
|
Time Factors | 4 | 1998 | 896 |
Why?
|
Sensitivity and Specificity | 2 | 2000 | 427 |
Why?
|
Substance Abuse, Intravenous | 2 | 1998 | 15 |
Why?
|
Health Services Misuse | 1 | 2010 | 12 |
Why?
|
Drug Resistance, Microbial | 4 | 1993 | 53 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2010 | 27 |
Why?
|
Oxazolidinones | 1 | 2010 | 1 |
Why?
|
Rifabutin | 2 | 2005 | 4 |
Why?
|
Demography | 1 | 2010 | 87 |
Why?
|
Acetamides | 1 | 2010 | 20 |
Why?
|
Latent Tuberculosis | 1 | 2009 | 1 |
Why?
|
Medication Adherence | 1 | 2009 | 19 |
Why?
|
Pregnancy | 3 | 2003 | 455 |
Why?
|
Practice Guidelines as Topic | 2 | 2007 | 174 |
Why?
|
Infant, Newborn | 2 | 2006 | 389 |
Why?
|
Prevalence | 3 | 2003 | 281 |
Why?
|
Hospitalization | 1 | 2010 | 169 |
Why?
|
Communication | 1 | 2010 | 116 |
Why?
|
Communicable Disease Control | 1 | 2007 | 20 |
Why?
|
AIDS Serodiagnosis | 1 | 2007 | 10 |
Why?
|
Drug Administration Schedule | 2 | 2005 | 191 |
Why?
|
Infant | 4 | 2002 | 464 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 321 |
Why?
|
Organizational Objectives | 1 | 2006 | 26 |
Why?
|
Social Responsibility | 1 | 2006 | 17 |
Why?
|
Private Sector | 1 | 2006 | 1 |
Why?
|
Public Sector | 1 | 2006 | 2 |
Why?
|
Ethambutol | 1 | 2006 | 1 |
Why?
|
Counseling | 1 | 2007 | 50 |
Why?
|
Reproducibility of Results | 1 | 2010 | 391 |
Why?
|
BCG Vaccine | 2 | 2003 | 22 |
Why?
|
DNA Transposable Elements | 2 | 2001 | 23 |
Why?
|
Aza Compounds | 1 | 2006 | 13 |
Why?
|
Program Development | 1 | 2006 | 61 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2005 | 145 |
Why?
|
Skin | 1 | 2008 | 177 |
Why?
|
Urban Health | 1 | 2006 | 47 |
Why?
|
Quinolines | 1 | 2006 | 26 |
Why?
|
United States | 3 | 2006 | 604 |
Why?
|
Socioeconomic Factors | 2 | 2003 | 144 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2006 | 35 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 1996 | 85 |
Why?
|
World Health | 1 | 2005 | 41 |
Why?
|
Risk Assessment | 2 | 2005 | 324 |
Why?
|
Microbial Sensitivity Tests | 4 | 1993 | 71 |
Why?
|
Workplace | 1 | 2003 | 16 |
Why?
|
Hospitals, Urban | 1 | 2003 | 10 |
Why?
|
Schools | 1 | 2003 | 28 |
Why?
|
CD4 Lymphocyte Count | 3 | 1996 | 50 |
Why?
|
Residence Characteristics | 1 | 2003 | 39 |
Why?
|
Community-Acquired Infections | 1 | 2003 | 17 |
Why?
|
Regression Analysis | 2 | 1998 | 256 |
Why?
|
Genetic Variation | 1 | 2003 | 91 |
Why?
|
Database Management Systems | 1 | 2002 | 11 |
Why?
|
Immunization Programs | 1 | 2003 | 24 |
Why?
|
Serologic Tests | 1 | 2002 | 24 |
Why?
|
Streptomycin | 1 | 2001 | 5 |
Why?
|
Age Factors | 1 | 2005 | 480 |
Why?
|
Drug Resistance, Multiple | 2 | 1997 | 19 |
Why?
|
Equipment Contamination | 1 | 2000 | 15 |
Why?
|
Prospective Studies | 3 | 1997 | 545 |
Why?
|
Mass Screening | 1 | 2003 | 125 |
Why?
|
Specimen Handling | 1 | 2000 | 52 |
Why?
|
Emigrants and Immigrants | 2 | 2008 | 9 |
Why?
|
Drug Interactions | 1 | 1999 | 111 |
Why?
|
HIV Seronegativity | 1 | 1998 | 13 |
Why?
|
Confidence Intervals | 1 | 1998 | 104 |
Why?
|
Proportional Hazards Models | 1 | 1998 | 123 |
Why?
|
Ambulatory Care Facilities | 2 | 2005 | 27 |
Why?
|
Data Interpretation, Statistical | 1 | 1998 | 109 |
Why?
|
Odds Ratio | 1 | 1998 | 157 |
Why?
|
Diagnostic Errors | 1 | 1997 | 73 |
Why?
|
Disease Progression | 1 | 1998 | 244 |
Why?
|
Survival Rate | 1 | 1998 | 250 |
Why?
|
Anti-HIV Agents | 2 | 2003 | 44 |
Why?
|
Referral and Consultation | 2 | 2006 | 134 |
Why?
|
Bacterial Typing Techniques | 2 | 2001 | 15 |
Why?
|
Tuberculin | 2 | 1996 | 4 |
Why?
|
Cost-Benefit Analysis | 2 | 2003 | 118 |
Why?
|
Virus Replication | 1 | 1996 | 90 |
Why?
|
Enterococcus | 1 | 1993 | 6 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 1993 | 16 |
Why?
|
Vancomycin | 1 | 1993 | 23 |
Why?
|
Comorbidity | 2 | 2003 | 190 |
Why?
|
Drug Users | 1 | 2011 | 3 |
Why?
|
Recurrence | 2 | 2001 | 261 |
Why?
|
Gastrointestinal Diseases | 1 | 2010 | 31 |
Why?
|
HIV-1 | 1 | 1996 | 93 |
Why?
|
Bone Marrow Diseases | 1 | 2010 | 31 |
Why?
|
Nervous System Diseases | 1 | 2010 | 78 |
Why?
|
African Americans | 1 | 2010 | 108 |
Why?
|
Substance-Related Disorders | 1 | 2010 | 96 |
Why?
|
Databases, Factual | 1 | 2008 | 102 |
Why?
|
Capreomycin | 1 | 2007 | 1 |
Why?
|
Drug Administration Routes | 1 | 2007 | 10 |
Why?
|
Radiography, Thoracic | 1 | 2007 | 41 |
Why?
|
Africa | 1 | 2006 | 4 |
Why?
|
Feasibility Studies | 1 | 2007 | 144 |
Why?
|
Patient Education as Topic | 1 | 2007 | 128 |
Why?
|
Prenatal Care | 1 | 2006 | 35 |
Why?
|
Population Surveillance | 1 | 2006 | 70 |
Why?
|
Drug Therapy, Combination | 1 | 2006 | 189 |
Why?
|
Treatment Failure | 1 | 2005 | 88 |
Why?
|
Occupational Diseases | 1 | 2005 | 51 |
Why?
|
Masks | 1 | 2003 | 8 |
Why?
|
Methadone | 1 | 2003 | 11 |
Why?
|
Infection Control | 1 | 2003 | 20 |
Why?
|
Pyrazinamide | 1 | 2003 | 1 |
Why?
|
Developing Countries | 1 | 2003 | 28 |
Why?
|
HIV | 1 | 2003 | 32 |
Why?
|
Interviews as Topic | 1 | 2003 | 94 |
Why?
|
Physician's Practice Patterns | 1 | 2006 | 149 |
Why?
|
Clinical Trials as Topic | 1 | 2007 | 251 |
Why?
|
Health Care Costs | 1 | 2003 | 73 |
Why?
|
New York | 1 | 2005 | 422 |
Why?
|
Breast Feeding | 1 | 2003 | 45 |
Why?
|
Bacteriological Techniques | 1 | 1997 | 29 |
Why?
|
Survivors | 1 | 1997 | 45 |
Why?
|
Cell Death | 1 | 1996 | 94 |
Why?
|
Lymphocytes | 1 | 1996 | 142 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 1996 | 91 |
Why?
|
Enterococcus faecalis | 1 | 1993 | 11 |
Why?
|
DNA Probes | 1 | 1993 | 61 |
Why?
|
Base Sequence | 1 | 1993 | 371 |
Why?
|
Molecular Sequence Data | 1 | 1993 | 404 |
Why?
|
